CalcMyPeptide
Weight ManagementAlso known as: BI 456906, GLP-1/glucagon dual agonist BI

Survodutide

Survodutide is a monstrously powerful dual GLP-1 and Glucagon agonist developed by Boehringer Ingelheim. Currently tearing through Phase 3 trials, it has posted outrageous clinical data demonstrating near 19% total body weight annihilation. Engineered to conquer both morbid obesity and advanced liver disease (MASH), it stands as one of the most aggressive metabolic reset compounds in the modern clinical pipeline.

Reviewed by CalcMyPeptide Editorial Team
Last updated: April 2026Evidence: Emerging1 peer-reviewed citation

Quick Stats

Half-Life~6-8 days (once weekly)
Dose Range0.6-6 mg/week
Frequency1× weekly
Vial Sizes2.4 mg, 4.8 mg
Bioavailability~85% SC (estimated)
Year Developed2022

Scientific Data

Molecular Formula
Acyl-modified GCGr/GLP-1R dual peptide
Molecular Weight
~4100 Da
Developer
Boehringer Ingelheim / Zealand Pharma

Mechanism of Action

Survodutide (BI 456906) is a dual glucagon/GLP-1 receptor agonist (GCGr/GLP-1R) developed by Boehringer Ingelheim and Zealand Pharma. It uses a higher glucagon-to-GLP-1 activity ratio than pemvidutide or mazdutide — with a design optimized for maximizing energy expenditure via glucagon receptor activity while retaining GLP-1-mediated appetite suppression and insulin modulation. Phase 2 MARCH-NASH trial showed significant MASH (metabolic dysfunction-associated steatohepatitis) resolution. Phase 3 obesity trials show up to 18.7% body weight reduction at 6 mg over 46 weeks.

Source: PMID: 38587239 (SYNCHRONIZE Phase 2)

Dosing Protocol

Typical Dose0.6-6 mg/week
Frequency1× weekly
Half-Life~6-7 days
Common Vial Sizes2.4 mg, 4.8 mg

Dosing Protocols

Phase 3 Escalation

Dose
0.6 mg → 2.4 mg → 6 mg
Frequency
Once weekly (SC)
Note: Escalation over 16 weeks. 6 mg is the top studied dose.

Administration

Route
Subcutaneous injection
Timing
Once weekly, same day each week.
Fasting Required?
No — food timing not critical

Expected Timeline

Month 1-3
Rapid energy expenditure increase from glucagon receptor agonism. Early MASH improvement signals.
Month 9-12
18.7% body weight reduction at 6 mg. MASH resolution in 65%+ of treated patients in Phase 2.

Who Is It For?

Obesity

High

Phase 3: 18.7% BWL at 6 mg over 46 weeks. Strong candidate for approval.

MASH (Liver Disease)

High

MARCH-NASH Phase 2: 65%+ MASH resolution rate — one of the highest observed for any drug in this indication.

Reconstitution Example

Vial
4.8 mg
Water
2 mL
Concentration
2.4 mg/mL
Per Unit (100u syringe)
24 mcg
Dose of 600 mcg = 25 units on a 100-unit insulin syringe
🧮 Calculate Your Exact Survodutide Dose →

Safety & Considerations

Investigational — not FDA-approved. Phase 3 obesity and MASH trials ongoing. GI profile consistent with GLP-1 class. Higher glucagon agonism means higher energy expenditure but potential for slightly more cardiovascular effects — monitoring ongoing in trials.

Regulatory & Legal Status

FDA Status (US)
Research Only
WADA Status (2026)
Not Listed

Not currently on the WADA 2026 Prohibited List. Policies may change — verify before competition.

Classification

Research Chemical

US Compounding: Not eligible / not available

⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.

Dosing Quick Reference

Survodutide— Dosing Guide
Dose Range
0.6-6 mg/week
Half-Life
~6-7 days
Frequency
1× weekly
Route
Subcutaneous
2.4 mg vial4.8 mg vial
💧 2 mL BAC water📐 2.4 mg/mL concentration💉 24 mcg/unit (100u syringe)
Weight Managementcalcmypeptide.com

Frequently Asked Questions

What makes survodutide different from tirzepatide?▼
Tirzepatide is GIP+GLP-1; survodutide is Glucagon+GLP-1. Glucagon receptor agonism is more directly linked to hepatic fat oxidation (making survodutide a leading MASH drug candidate) while GIP helps insulin sensitization in adipose tissue.
Is survodutide FDA-approved?▼
No — Phase 3 trials are ongoing. Phase 2 MASH data is promising enough that Boehringer Ingelheim has initiated Phase 3 MASH and obesity pivotal trials.

References

  1. Lautenbach A et al. “"Survodutide for overweight/obesity (Phase 2)".” Nature Medicine (2024).

📚 Related Articles

GLP-1 Dose Escalation Guide: Semaglutide, Tirzepatide & Retatrutide
14 min read • Pillar Guide

Looking for a trusted source? See our recommended suppliers →

Independently tested · COA-verified · Save 10% with our exclusive code

← Back to Peptide Library